Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine (T3) Augmentation for Bipolar Depression
NCT00790738Phase 3
Key facts
- Status
- Completed
- Start
- Jul 2008
- Primary completion
- Jul 2012
- Countries
- 1
- Sponsor
- Northwell Health
- Modality
- Small Molecules
- Drugs
- liothyronine
- Conditions
- bipolar disorder (BD)
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Liothyronine (T3) with Placebo (2 arms). Primary endpoint: Hamilton Rating Scale for Depression at 8 weeks. Started Jul 2008; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Liothyronine (T3)
Liothyronine (up to 50 mcg/day) + Treatment as Usual
Placebo
Placebo + Treatment as Usual
03
Endpoints
Primary
Hamilton Rating Scale for Depression
Secondary
Clinician-Administered Rating Scale for Mania
Clinical Global Impression
Beyond the preview
Go deeper on NCT00790738.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00790738.